CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa

Table 2 Multiple linear regression models estimating the average change in CD4 cell count per month (CD4 slope). Separate models analyse the first (0 – 16 weeks) and second (16 – 48 weeks) phases of immune recovery during ART.

		Phase 1 (0–16 weeks) CD4 slope (n = 596)			Phase 2 (16–48 weeks) CD4 slope (n = 311)¹
		Mean	(95% CI)	P value	Mean	(95% CI)	P value
Age (years)	<30	1.0			1.0
	30–39	-2,27	(-6.71,2.17)	0.32	-2.18	(-5.98, 1.63)	0.26
	>40	-2.17	(-7.87, 3.54)	0.46	-7.31	(-12.11, -2. 50)	0.003
Sex	Female	1.0			1.0
	Male	-3.60	(-8.22, 1.02)	0.13	-0.94	(-4.98, 3.10)	0.65
Baseline CD4 coimt (cells/μl)	>150	1.0			1.0
	100–149	3.85	(-1.63, 9.33)	0,17	-2.17	(-7.09, 2.76)	0.39
	50–99	3.53	(-1.84, 8.91)	0.20	0.93	(-4.22, 6.08)	0.72
	<50	2.34	(-3.31, 7.98)	0.42	8.55	(2.39, 14.71)	0.007
WHO clinical stage	1 & 2	1.0			1.0
	3	1.79	(-3.33, 6.91)	0.49	-0.70	(-5.40, 4.00)	0.77
	4	0.55	(-5.39, 6.49)	0.86	-1.76	(-6.93, 3.41)	0.50
Baseline viral load (copies/ml)	<5 log₁₀	1.0			1.0
	>5 log₁₀	11.14	(7.10, 15.18)	<0.001	2.21	(-1.37, 5.80)	0.23

¹ The Phase 2 model included as covariates all variables shown, as well the phase 1 CD4 cell slope, the CD4 cell count at 16 weeks and the viral load at 16 weeks (see text).

ISSN: 1471-2334